LeMaitre Vascular (LMAT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and LeMaitre Vascular published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. LeMaitre Vascular reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, excluding the Employee Retention Tax Credit, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q3 2025 results included a non-recurring benefit from the Employee Retention Tax Credit ($0.13 per share). LeMaitre's adjusted figures exclude it, so Q3 2025 adjusted EPS was $0.62 against $0.75 reported. Q3 2026 has no such item, so adjusted and GAAP EPS are both $0.65.
• In October 2026 LeMaitre acquired certain vascular assets from B. Braun for $19.2 million. Q3 2026 sales do not include them.

Source: LeMaitre Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How LeMaitre Vascular splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• LeMaitre Vascular's Americas revenue was $42.7 million in Q3 2026, up 9% from $39.2 million in Q3 2025, 63% of total revenue.
• LeMaitre Vascular's Europe, Middle East and Africa revenue was $20.8 million in Q3 2026, up 18% from $17.6 million in Q3 2025, 31% of total revenue.
• LeMaitre Vascular's Asia Pacific revenue was $4.4 million in Q3 2026, up 5% from $4.2 million in Q3 2025, 7% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

LeMaitre's outlook table gives Q4 2026 first and full year 2026 second on each line.

In its Q3 2026 release, LeMaitre Vascular said:

“We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%).”

“Sales $69.9mm - $71.9mm (Mid $70.9mm, +10%, +11% org.) $274.8mm - $276.8mm (Mid $275.8mm, +11%, +11% org.)”

“EPS $0.70 - $0.75 (Mid $0.73, +7%) $2.77 - $2.82 (Mid $2.80, +11%, +18% adj.)”

“LeMaitre anticipates recording ~$150,000 of Q4 2026 B. Braun product sales and break-even operating income impact.”

Source: LeMaitre Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the LMAT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and GAAP diluted EPS, each as first reported in that quarter's release. Q3 2025 EPS includes the Employee Retention Tax Credit benefit.

We do not hold a confirmed date for LeMaitre Vascular's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

LeMaitre Vascular reported net sales of $68.0 million in Q3 2026, up 11% from $61.0 million a year earlier, and 12% organic growth, which LeMaitre says was 7% price and 5% units. LeMaitre sells devices and implants for peripheral vascular disease to vascular surgeons, and grafts and shunts led the quarter: graft sales rose 20% and shunt sales 14%, and Artegraft sales rose 18%. (LeMaitre Q3 2026 release, Nov 4, 2026)

LeMaitre Vascular's 10-Q adds the dollar detail. Graft sales increased $4.5 million, shunt sales $0.9 million and valvulotome sales $0.5 million, helped by international sales of Artegraft after its European launch in the second half of 2025. LeMaitre estimates the stronger U.S. dollar reduced net sales by $0.4 million. (LeMaitre Form 10-Q, Q3 2026, Nov 5, 2026)

By region, Americas net sales were $42.7 million, 63% of the total, up 9%; Europe, Middle East and Africa $20.8 million, up 18%; and Asia Pacific $4.4 million, up 5%. LeMaitre's sales force reached 171 reps, up 13%, across a 31-country sales organization. (LeMaitre Q3 2026 release, Nov 4, 2026)

In October 2026 LeMaitre Vascular bought certain vascular assets from B. Braun for $19.2 million: polyester and silver-coated grafts, valve cutters and vein strippers that recorded sales of $9.4 million in 2025, all outside North America. LeMaitre expects those sales to move into its own channel over the next 18-24 months as B. Braun's customer contracts end or transfer. (LeMaitre Q3 2026 release, Nov 4, 2026)

LeMaitre Vascular's diluted EPS was $0.65 in Q3 2026, down 14% from $0.75. The year-ago quarter included a non-recurring Employee Retention Tax Credit worth $0.13 per share; excluding it, Q3 2025 EPS was $0.62 and Q3 2026 EPS rose 5%. Net income was $15.0 million, against $17.4 million. (LeMaitre Q3 2026 release, Nov 4, 2026)

Gross margin was 71.7%, against 75.3% reported and 70.8% adjusted a year earlier, and LeMaitre credits higher average selling prices and operational efficiencies for the adjusted improvement. Operating expenses rose 18% on an adjusted basis to $31.0 million, which LeMaitre attributes to belt-tightening in Q3 2025, and headcount rose 7% to 678. (LeMaitre Q3 2026 release, Nov 4, 2026)

LeMaitre Vascular's effective income tax rate was 23.6% in the quarter. Diluted weighted average shares were 23,071 thousand, against 24,392 thousand a year earlier. The board approved a quarterly dividend of $0.25 per share, up from $0.20, and in February 2026 authorized repurchases of up to $100.0 million of stock through February 18, 2027. (LeMaitre Form 10-Q, Q3 2026, Nov 5, 2026; LeMaitre Q3 2026 release, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

LeMaitre Vascular gives quarterly and full-year guidance in its release. For Q4 2026 it expects sales of $69.9 million to $71.9 million, gross margin of 72.1% and EPS of $0.70 to $0.75. For full year 2026 it expects sales of $274.8 million to $276.8 million, operating income of $74.6 million to $76.1 million and EPS of $2.77 to $2.82, with the $2.80 midpoint up 18% on an adjusted basis. (LeMaitre Q3 2026 release, Nov 4, 2026)

The outlook includes the B. Braun assets, which LeMaitre expects to add about $150,000 of Q4 2026 sales at break-even operating income. During the transition LeMaitre will receive a portion of the profits on B. Braun-originated sales. (LeMaitre Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover LeMaitre Vascular, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones LeMaitre Vascular's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning LMAT is on is LMAT a buy or a sell?, what analysts expect next is on the LMAT forecast, and what the company does is on the LeMaitre Vascular (LMAT) stock page.

Every number on this page can be traced to a document LeMaitre Vascular published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.